Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBT: 2015-2025

Historic EBT for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$104.8 million.

  • Intellia Therapeutics' EBT rose 21.02% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$486.5 million for FY2024, which is 4.51% down from last year.
  • As of Q3 2025, Intellia Therapeutics' EBT stood at -$104.8 million, which was down 2.11% from -$102.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' EBT registered a high of -$46.2 million during Q1 2021, and its lowest value of -$143.7 million during Q1 2022.
  • Its 3-year average for EBT is -$115.6 million, with a median of -$118.4 million in 2023.
  • In the last 5 years, Intellia Therapeutics' EBT slumped by 211.02% in 2022 and then surged by 30.43% in 2023.
  • Over the past 5 years, Intellia Therapeutics' EBT (Quarterly) stood at -$79.9 million in 2021, then crashed by 31.06% to -$104.7 million in 2022, then decreased by 21.67% to -$127.4 million in 2023, then climbed by 1.27% to -$125.8 million in 2024, then increased by 21.02% to -$104.8 million in 2025.
  • Its EBT was -$104.8 million in Q3 2025, compared to -$102.6 million in Q2 2025 and -$112.2 million in Q1 2025.